Alexion Pharmaceuticals Inc (ALXN)

ALXN (NASDAQ:Drugs) EQUITY
$143.46
pos +7.00
+5.10%
Today's Range: 136.76 - 142.52 | ALXN Avg Daily Volume: 1,643,500
Last Update: 02/10/16 - 1:03 PM EST
Volume: 754,343
YTD Performance: -27.05%
Open: $137.18
Previous Close: $136.46
52 Week Range: $130.51 - $208.88
Oustanding Shares: 225,324,303
Market Cap: 31,353,876,762
6-Month Chart
TheStreet Ratings Grade for ALXN
Buy Hold Sell
A+ A A- B+ B B- C+ C C- D+ D D- E+ E E- F
TheStreet Ratings is the source for accurate ratings that you can rely upon to make sound, informed financial decisions. Click here to find out about our methodology.
Analysts Ratings
Historical Rec Current 1 Mo. Ago 2 Mo. Ago 3 Mo. Ago
Strong Buy 14 12 11 11
Moderate Buy 1 1 1 1
Hold 3 3 3 3
Moderate Sell 0 0 0 0
Strong Sell 0 0 0 0
Mean Rec. 1.36 1.41 1.43 1.43
Latest Dividend: 0.00
Latest Dividend Yield: 0.00%
Dividend Ex-Date: 12/31/69
Price Earnings Ratio: 207.69
Price Earnings Comparisons:
ALXN Sector Avg. S&P 500
207.69 208.10 26.96
Price Performance History (%Change):
3 Mo 1 Yr 3 Y
-19.17% -22.30% 48.57%
GROWTH 12 Mo 3 Yr CAGR
Revenue 44.00 1.30 0.32
Net Income -78.00 -0.43 -0.17
EPS -79.50 -0.49 -0.20
Earnings for ALXN:
EBITDA 0.80B
Revenue 2.60B
Average Earnings Estimates
Qtr (03/16) Qtr (06/16) FY (12/16) FY (12/17)
Average Estimate $0.81 $0.91 $3.83 $5.41
Number of Analysts 3 3 3 2
High Estimate $1.01 $1.05 $4.41 $5.84
Low Estimate $0.55 $0.66 $2.89 $4.97
Prior Year $1.07 $1.13 $4.55 $3.83
Growth Rate (Year over Year) -23.99% -19.47% -15.82% 41.12%
Chart Benchmark Timeframe
Average Frequency Indicator Chart
Scale Symbol Comparison Bollinger Bands
By

Bruce Kamich

 | Feb 8, 2016 | 1:32 PM EST

The next potential support levels are the $120 and $100 areas from 2013.

By

Jared Woodard

 | Nov 30, 2015 | 11:50 AM EST

ILMN's three-month at-the-money implied volatility is at about the median level.

bullishAlexion upgraded at Morgan Stanley

Oct 2, 2015 | 7:50 AM EDT

ALXN was upgraded to Overweight, Morgan Stanley said. $211 price target. Orphan drugs should not face pricing concerns and the company has significant pipeline catalysts. 

By

Jim Cramer

 | May 18, 2015 | 3:24 PM EDT

Acquisitions cut into overabundance of companies.

By

David Peltier

 | May 6, 2015 | 4:52 PM EDT

U.S. stocks fell for a second straight session.

By

Jim Cramer

 | Mar 23, 2015 | 6:00 AM EDT

Here are healthcare stocks of all shares and sizes with strong charts.

bearishAlexion estimates, target cut at Credit Suisse

Jan 30, 2015 | 7:49 AM EST

Shares of ALXN now seen reaching $186, according to Credit Suisse. Estimates also reduced, given the company's currency headwinds. Neutral rating. 

By

Timothy Collins

 | Jan 8, 2015 | 10:09 AM EST
Do you need to pick one name?
By

Kate Stalter

 | Jan 6, 2015 | 12:00 PM EST

They are prone to being whipsawed by news.

bearishAlexion downgraded at Morgan Stanley

Jan 5, 2015 | 6:36 AM EST

ALXN was downgraded from Overweight to Equal-weight, Morgan Stanley said. $202 price target. Valuation call, as the company has limited near-term catalysts. 

Markets still in green across the board but hard to call this a "conviction" rally. Nice ...

C - an explanation coming up in my Diary.

Markets up on some more dovish comments about future rate hikes from Yellen, but have give...
Remember when First Data was returned to public trading in October? Of course, this is no...

REAL MONEY PRO'S BEST IDEAS

News Breaks

Powered by
Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data provided by Interactive Data. Company fundamental data provided by Morningstar. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by Interactive Data Managed Solutions.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

IDC calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.